Menu
 

Search abstracts


Evaluations of risk factors of uti in patients with type 2 dm taking sglt2 inhibitors

  • At: 2018 FIP Congress in Glasgow (Scotland)
  • Type: Poster
  • By: HUANG, Yu-Chen (MacKay Memorial Hospital, Pharmacy)
  • Co-author(s): Yu-Chen Huang: Pharmacy, MacKay Memorial Hospital, Hsinchu, Taiwan, Province of China
    Kai-Hsun Lo: Pharmacy, MacKay Memorial Hospital, Hsinchu, Taiwan, Province of China
    Hsiao-Huai Kuo: Pharmacy, MacKay Memorial Hospital, Hsinchu, Taiwan, Province of China
    Yatzu Hu: Pharmacy, MacKay Memorial Hospital, Hsinchu, Taiwan, Province of China
  • Abstract:

    Background

    Sodium glucose co-transporter-2 (SGLT2) inhibitors decrease blood glucose by increasing urinary glucose excretion, which increases the risk of urinary tract infection (UTI) in patients with type 2 diabetes mellitus (T2DM).

    Methods

    We reviewed medical records of patients who were diagnosed T2DM and used dapagliflozin or empagliflozin in

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 13 May 2019

FIP Congresses